Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol 2015; 7(1): 53-69 [PMID: 25624997 DOI: 10.4254/wjh.v7.i1.53]
Corresponding Author of This Article
Gerrit Koopman, PhD, Department of Virology, Biomedical Primate Research Centre, PO Box 3306, 2280GH Rijswijk, The Netherlands. koopman@bprc.nl
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jan 27, 2015; 7(1): 53-69 Published online Jan 27, 2015. doi: 10.4254/wjh.v7.i1.53
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees
Babs E Verstrepen, André Boonstra, Gerrit Koopman
Babs E Verstrepen, Gerrit Koopman, Department of Virology, Biomedical Primate Research Centre, 2280GH Rijswijk, The Netherlands
André Boonstra, Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, 3015 CE Rotterdam, The Netherlands
Author contributions: Verstrepen BE, Boonstra A and Koopman G wrote the paper.
Supported by In part the Fifth framework program from the EU, No. BIO-CT98-0357, QLK2-CT-1999-00356 and ERC-2008-AdG-233130-HEPCENT (Verstrepen BE); by the Virgo consortium, funded by the Dutch government project, No. FES0908 (Boonstra A)
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gerrit Koopman, PhD, Department of Virology, Biomedical Primate Research Centre, PO Box 3306, 2280GH Rijswijk, The Netherlands. koopman@bprc.nl
Telephone: +31-15-2842761
Received: August 27, 2014 Peer-review started: August 31, 2014 First decision: September 28, 2014 Revised: October 22, 2014 Accepted: November 7, 2014 Article in press: November 10, 2014 Published online: January 27, 2015 Processing time: 135 Days and 20 Hours
Abstract
Hepatitis C virus (HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently, there is no approved prophylactic HCV vaccine available. With the near disappearance of the most relevant animal model for HCV, the chimpanzee, we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees, in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved, but a clear correlate of protection has thus far not yet been defined.
Core tip: With the near disappearance of the most relevant animal model for hepatitis C virus (HCV), the chimpanzee, we review the progression that has been made regarding vaccine development against this virus infection. An estimated 3 million people suffering from chronic hepatitis caused by HCV die each year. Currently, there is no approved vaccine available to prevent new infection.
